Shareholders of Blue Foundry Bancorp have voted decisively to approve the company's merger agreement with Fulton Financial Corporation, clearing a critical hurdle in the creation of a stronger regional banking entity.
Novo Nordisk's newly launched oral GLP-1 drug, amycretin, has seen explosive initial demand in the U.S., potentially setting the stage for a significant financial turnaround and stock rally after a challenging previous year.
Well-intentioned financial guidance from previous generations often fails to account for today's economic realities. From home ownership to savings accounts, we examine the advice that hasn't aged well and what you should consider instead.
As Pony AI Inc. slashes hardware costs by 70% and plans a major fleet expansion, investors are weighing its potential as a high-stakes bet on the future of self-driving cars in key Asian markets.
Viasat shares have rocketed 31% in a month, reigniting investor debate over whether the satellite communications firm is a hidden gem or a momentum-driven play facing stiff competition from SpaceX's Starlink and Amazon's Project Kuiper.
Bernstein raises UPS price target to $128, citing robust fourth-quarter results that help balance a softer margin outlook. The logistics giant's strategic pivot away from low-margin Amazon business and ongoing cost-cutting measures shape its 2026 trajectory.
JPMorgan raises Edison International's price target to $66, citing model updates ahead of earnings. The utility giant, noted for its sustainable high-yield dividend, continues to benefit from California's electrification trends and regulated investment framework.
Canadian National Railway reported robust fourth-quarter earnings and improved operational efficiency for 2025, yet management offered a more guarded, volume-dependent outlook for the coming year, citing persistent headwinds from tariffs and a volatile trade environment.
Cavco Industries' fiscal Q3 2026 results reflect the initial impact of its American Homestar acquisition amid broader industry headwinds. While revenue grew, margins contracted due to integration costs and a seasonal demand slowdown. Management points to stable backlogs and strategic positioning for the upcoming spring selling season.
The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.
Specialty metals maker Carpenter Technology posted record Q2 sales and raised its full-year operating income outlook, yet its stock fell sharply. The divergence highlights investor concerns over valuation and the company's heavy dependence on the aerospace cycle, even as demand in the sector remains robust.
Altria Group names CFO Salvatore Mancuso as its incoming CEO, accelerating its smoke-free transition while taking a massive impairment charge on past investments, signaling a sharp strategic reassessment.
Facing its weakest annual profit in years, Eastman Chemical is doubling down on cost reductions while banking on its molecular recycling technology to fuel a turnaround by 2026, despite a challenging global economic climate.
Despite a challenging mortgage landscape, SB Financial Group (SBFG) reports robust fourth-quarter and full-year 2025 results, marking one of its strongest performances in history with significant loan growth and disciplined expense management.
First Hawaiian Bank reported a solid fourth quarter, driven by net interest margin expansion and loan growth, while outlining a cautious 2026 outlook. Executives highlighted Hawaii's resilient economy and strong credit quality, alongside a new, flexible $250 million share buyback program.
Truist Securities raised its price target on Fifth Third Bancorp (FITB) following a robust quarterly performance driven by loan growth and fee income, while slightly adjusting its long-term earnings outlook due to acquisition timing and tax considerations.
As Palantir Technologies prepares to report Q4 results, options markets signal significant volatility ahead, with the stock's AI-driven rally facing a reality check amid shifting investor focus.
New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
RBC Capital reaffirms its Outperform rating on UnitedHealth Group, citing management's commitment to long-term earnings targets, even as a lower-than-expected Medicare Advantage rate proposal triggers a sharp sell-off in the health insurer's shares.
Bitcoin struggles to find a floor, trading near November lows as the nomination of Kevin Warsh for Fed Chair fails to spark a rally. Persistent outflows from US spot ETFs and a broader risk-off mood compound the pressure, raising fresh doubts about the cryptocurrency's 'digital gold' narrative.
